MEF2A (Ab-319) Antibody

What is MEF2A and what are its key biological functions?

MEF2A (Myocyte Enhancer Factor 2A) is a transcription factor belonging to the MADS gene family. It functions as a transcriptional activator that binds specifically to the MEF2 element (5'-YTAATTAR-3') found in numerous muscle-specific genes .

MEF2A plays diverse roles in:

• Skeletal and cardiac muscle development

• Neuronal differentiation and survival

• Cell growth, survival, and apoptosis via p38 MAPK signaling

• Activation of growth factor and stress-induced genes

MEF2A is highly expressed in various tissues and participates in multiple regulatory networks involving growth, differentiation, survival, and cell death . In neurons, phosphorylated and sumoylated MEF2A represses transcription of NUR77, promoting synaptic differentiation .

What epitope does the MEF2A (Ab-319) Antibody recognize?

The MEF2A (Ab-319) Antibody specifically recognizes the peptide sequence around amino acids 317-321 (V-T-T-P-S) derived from Human MEF2A . This region is significant as it contains the Threonine 319 residue, which is a p38 MAPK-dependent phosphorylation site that can markedly increase the transcriptional activity of MEF2A when phosphorylated .

The antibody detects endogenous levels of total MEF2A protein, regardless of phosphorylation status at this site . This distinguishes it from phospho-specific antibodies that only detect MEF2A when phosphorylated at specific residues.

What are the recommended applications for MEF2A (Ab-319) Antibody?

When designing experiments, researchers should consider using positive controls such as tissues or cell lines known to express high levels of MEF2A (e.g., cardiomyocytes, as MEF2A is abundantly expressed in these cells) .

How does the host species and clonality affect experimental design?

The MEF2A (Ab-319) Antibody is a rabbit polyclonal antibody , which has important implications for research applications:

• Polyclonal nature: The antibody recognizes multiple epitopes on the target protein, potentially increasing sensitivity but may also increase background compared to monoclonal antibodies.

• Host species considerations: Being rabbit-derived, this antibody should not be used with secondary anti-rabbit antibodies in rabbit tissues without proper blocking to prevent non-specific binding.

• Multiple detection: For co-localization studies, researchers should pair this rabbit polyclonal with antibodies raised in different host species (e.g., mouse, goat) to avoid cross-reactivity with secondary antibodies.

The antibody is purified via affinity chromatography using epitope-specific peptide , which helps reduce non-specific binding.

How do post-translational modifications affect MEF2A function and detection?

MEF2A undergoes multiple post-translational modifications that significantly affect its function:

• Phosphorylation:

  • Thr312 and Thr319 are p38 MAPK-dependent phosphorylation sites that markedly increase MEF2A transcriptional activity when phosphorylated

  • Ser255 phosphorylation can affect protein stability and function; excessive phosphorylation by GSK3 may lead to MEF2A degradation and neuronal apoptosis

• Acetylation and Sumoylation:

  • These modifications also regulate MEF2A activity and are particularly important in neurons

For researchers specifically interested in phosphorylation states:

• Use phospho-specific antibodies (e.g., anti-MEF2A pThr319) to detect activated MEF2A

• Compare with total MEF2A antibodies to determine the ratio of active vs. total protein

• Consider lambda phosphatase treatment as a negative control to confirm phospho-specificity

In oxidative stress conditions, moderate oxidative stress (200-400 μM H₂O₂) increases MEF2A degradation and activity, while excessive oxidative stress (>400 μM H₂O₂) halts degradation, resulting in accumulation of non-functional MEF2A with harmful cellular effects .

What role does MEF2A play in genomic integrity and inflammation?

Recent research has revealed that MEF2A plays a crucial role in maintaining genomic integrity and preventing unscheduled inflammation:

• R-loop regulation:

  • MEF2A depletion leads to excessive accumulation of R-loops (RNA:DNA hybrids)

  • This accumulation can be detected using S9.6 antibodies specific for RNA:DNA hybrids

  • RNase H treatment, which specifically degrades RNA:DNA hybrid strands, can be used as a control to confirm R-loop accumulation

• DDX41/STING-mediated inflammation:

  • Loss of MEF2A drives DDX41/STING-mediated interferon (IFN) responses

  • This pathway leads to spontaneous IFN production and a downstream cellular antiviral state

  • DDX41-deficient cells show attenuated responses upon MEF2A depletion, confirming the pathway dependency

• DNA damage response:

  • MEF2A depletion leads to accumulation of phosphorylated histone 2AX (γH2A.X), a marker of DNA damage

  • This pathway is distinct from ER stress responses, as MEF2A depletion did not lead to accumulation of ATF4 or enhanced splicing of XBP1

For researchers studying these pathways, it's important to use appropriate controls and methods:

• Compare STING knockout cells with wild-type cells when studying MEF2A-dependent inflammation

• Use RNase H treatment as a control when assessing R-loop formation

• Include DDX41-deficient cell lines to confirm pathway specificity

How does MEF2A function in different disease contexts?

MEF2A exhibits context-dependent roles in various pathological conditions:

In Cancer:

• MEF2A can support either oncogenic or tumor suppressive activity depending on co-factors

• In leiomyosarcoma, class II HDAC expression levels determine whether MEF2A inhibits or promotes tumors

• MEF2A promotes progression in multiple myeloma and colorectal cancer

• In gastric cancer, MEF2A can:

  • Promote glucose uptake and cell growth via GLUT-4 upregulation (when activated by p38 MAPK)

  • Inhibit cancer progression by activating lncRNA HCP5 expression

  • Promote KLF4 expression (when activated by epigallocatechin-3-gallate) to inhibit cancer cell growth

In Neurological Conditions:

• In autism spectrum disorder (ASD), MEF2A has been identified as a link between oxytocin and cellular changes symptomatic of ASD

• Disruption of functional MEF2 and accumulation of function-impaired MEF2 are harmful for neuronal survival

• MEF2A knockout affects hippocampal neurogenesis by increasing neuron numbers but impairing dendrite development

Researchers should consider these context-dependent effects when designing experiments and interpreting results involving MEF2A in disease models.

What methodological considerations are important when detecting MEF2A in different experimental systems?

When studying MEF2A across different experimental systems, researchers should consider:

Cell Line Selection:

• Human cardiomyocyte cell lines (e.g., AC16) express high levels of MEF2A and are suitable for studies on MEF2A function in cardiac cells

• Hypothalamic cell lines can be used to study MEF2A in neuroendocrine contexts:

  • The rat H32 cell line can be subjected to CRISPR-Cas-mediated knockout of MEF2A

  • Mouse hypothalamic mHypoE-N11 cells naturally lack MEF2A expression and can be used for MEF2A overexpression studies

MEF2A Manipulation Approaches:

• Transient knockdown:

  • siRNA-mediated depletion captures acute gene expression changes while avoiding compensation by other MEF2 paralogs

  • Multiple MEF2A-targeting siRNAs should be tested to validate reproducibility

• CRISPR-Cas knockout:

  • Generates complete MEF2A-null cells for long-term functional studies

  • Can be complemented with re-expression of wild-type or mutant MEF2A

• Site-directed mutagenesis:

  • Mutations at S408D can mimic permanently phosphorylated and transcriptionally inactive MEF2A

  • Phospho-mimetic or phospho-dead mutations at Thr319 can be used to study the role of this specific post-translational modification

Detection Methods:

• For phosphorylated MEF2A, use phospho-specific antibodies (e.g., Phospho-MEF2A (Thr319) Antibody)

• For total MEF2A, use antibodies like MEF2A (Ab-319) that detect the protein regardless of phosphorylation status

• Consider subcellular fractionation to distinguish nuclear from cytoplasmic MEF2A pools

How do MEF2A levels correlate with interferon responses and antiviral states?

Research has revealed important connections between MEF2A and innate immune responses:

• MEF2A depletion and IFN production:

  • Acute depletion of MEF2A drives spontaneous IFN production and a downstream cellular antiviral state

  • Gene ontology analysis of MEF2A-depleted cells shows significant enrichment in pathways associated with innate immune inflammation and type I IFN responses

  • MEF2A silencing leads to phosphorylation of the IFN-responsive transcription factor STAT1 at tyrosine 701 (Y701)

• Antiviral protection:

  • MEF2A loss confers protection against cardiotropic viruses such as Coxsackievirus B3 (CVB3)

  • Media from MEF2A-depleted cells can establish an antiviral state when transferred to naive cells

• Pathway dependency:

  • The IFN response following MEF2A depletion depends on STING but is independent of cGAS and IFI16

  • DDX41 is required for IRF3 activation and STAT1 phosphorylation in this context

For researchers studying these mechanisms:

• Use ELISA or bioassays to quantify type I and III IFN secretion following MEF2A manipulation

• Include neutralizing antibodies against IFN receptors to confirm the specificity of the antiviral effects

• Consider viral protection assays to evaluate the functional significance of MEF2A-mediated IFN responses

What controls should be included when using MEF2A (Ab-319) Antibody?

When designing experiments with MEF2A (Ab-319) Antibody, include these essential controls:

Positive Controls:

• Cell lines with known high MEF2A expression (cardiomyocytes, neurons)

• Recombinant MEF2A protein for Western blotting

• Tissues with documented MEF2A expression (heart, brain, skeletal muscle)

Negative Controls:

• MEF2A knockout cell lines (CRISPR-Cas9 generated)

• Cell lines with naturally low MEF2A expression (e.g., mHypoE-N11)

• Pre-adsorption of antibody with immunizing peptide to demonstrate specificity

• Secondary antibody-only controls to detect non-specific binding

Validation Approaches:

• Use multiple MEF2A antibodies targeting different epitopes to confirm specificity

• For phosphorylation studies, include lambda phosphatase treatment to remove phosphate groups

• When studying R-loops, include RNase H treatment as a control to confirm RNA:DNA hybrid specificity

How can researchers optimize immunohistochemistry protocols for MEF2A (Ab-319) Antibody?

For optimal IHC results with MEF2A (Ab-319) Antibody:

Pre-treatment Optimization:

• Test multiple antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0)

  • HIER with EDTA buffer (pH 9.0)

  • Enzymatic retrieval with proteinase K

• Optimize retrieval time based on tissue type and fixation method

Antibody Dilution and Incubation:

• Start with the recommended dilution range (1:50~1:100)

• Test both overnight incubation at 4°C and shorter incubations at room temperature

• Consider signal amplification systems for low-abundance targets

Reducing Background:

• Include thorough blocking steps with serum from the same species as the secondary antibody

• Use of avidin/biotin blocking for tissues with endogenous biotin

• Consider tyramide signal amplification for enhanced sensitivity without increased background

Counterstaining and Visualization:

• Nuclear counterstaining with hematoxylin helps visualize MEF2A's predominantly nuclear localization

• For fluorescent detection, DAPI counterstaining allows clear visualization of nuclear MEF2A

How to interpret conflicting MEF2A expression data across different experimental systems?

When facing contradictory results regarding MEF2A expression or function:

• Consider context-dependent regulation:

  • MEF2A function varies by tissue type and developmental stage

  • Post-translational modifications significantly alter MEF2A activity and stability

  • MEF2A can have opposing roles in different disease contexts (tumor promoting vs. suppressing)

• Methodological factors:

  • Different antibodies may recognize different epitopes or conformational states

  • Total MEF2A vs. phosphorylated MEF2A detection can yield different results

  • RNA expression (RT-qPCR) vs. protein detection methods may show discrepancies

• Technical validation steps:

  • Confirm antibody specificity using knockout controls

  • Validate with multiple detection methods (WB, IHC, IF)

  • Use targeted knockdown with multiple siRNAs to confirm specificity

  • Consider subcellular fractionation to distinguish nuclear vs. cytoplasmic pools

• Complementary approaches:

  • Combine protein detection with functional assays

  • Use reporter gene assays to measure MEF2A transcriptional activity

  • Consider chromatin immunoprecipitation to assess MEF2A binding to target genes

What are the key considerations when studying MEF2A phosphorylation at Thr319?

For researchers investigating the specific phosphorylation at Thr319:

• Antibody selection:

  • Use phospho-specific antibodies that detect MEF2A only when phosphorylated at Thr319

  • Compare with total MEF2A antibodies to determine the proportion of phosphorylated protein

• Induction conditions:

  • p38 MAPK activation is required for phosphorylation at Thr319

  • Consider using p38 MAPK activators (e.g., anisomycin, UV radiation, inflammatory cytokines)

  • Use p38 MAPK inhibitors (e.g., SB203580) as negative controls

• Functional validation:

  • Generate phospho-mimetic (T319D/E) and phospho-dead (T319A) mutants

  • Compare transcriptional activity using reporter gene assays

  • Assess protein stability and localization of mutant variants

• Technical considerations:

  • Include phosphatase inhibitors in all buffers during sample preparation

  • Use Phos-tag™ SDS-PAGE for enhanced separation of phosphorylated proteins

  • Consider mass spectrometry to identify multiple phosphorylation sites simultaneously

What emerging techniques could enhance MEF2A research?

Several cutting-edge approaches could advance MEF2A research:

• Single-cell technologies:

  • Single-cell RNA-seq to identify cell-specific MEF2A expression patterns

  • Single-cell ATAC-seq to correlate MEF2A binding with chromatin accessibility

  • Mass cytometry (CyTOF) for simultaneous detection of multiple phosphorylation states

• Genome editing approaches:

  • CRISPR activation/inhibition systems for targeted modulation of MEF2A expression

  • Base editing for precise mutation of phosphorylation sites

  • CRISPR knock-in of fluorescent tags for live-cell imaging of MEF2A dynamics

• Structural biology methods:

  • Cryo-EM structures of MEF2A in complex with DNA and cofactors

  • Hydrogen-deuterium exchange mass spectrometry to study conformational changes upon phosphorylation

  • AlphaFold or similar AI-based structural prediction of full-length MEF2A

• Multi-omics integration:

  • Combining ChIP-seq, RNA-seq, and proteomics data to build comprehensive MEF2A regulatory networks

  • Spatial transcriptomics to map MEF2A expression in tissue contexts

  • Systems biology approaches to model MEF2A-dependent cellular responses

How might understanding MEF2A biology contribute to therapeutic development?

MEF2A research could inform several therapeutic approaches:

• In inflammatory disorders:

  • The MEF2A-DDX41-STING pathway represents a potential target for modulating type I IFN responses

  • Understanding R-loop regulation by MEF2A could inform strategies to prevent inflammation driven by nucleic acid sensing

• In cardiovascular disease:

  • MEF2A's role in cardiomyocyte function makes it relevant for cardiac pathologies

  • Targeting post-translational modifications of MEF2A could modulate cardiac gene expression programs

• In neurological conditions:

  • MEF2A's involvement in oxytocin-induced effects relevant to autism spectrum disorder highlights potential therapeutic avenues

  • The role of MEF2A in neuronal survival and dendrite development suggests applications in neurodegenerative diseases

• In cancer:

  • Context-dependent roles of MEF2A in tumor promotion or suppression suggest tailored approaches:

    • Inhibiting MEF2A function in cancers where it promotes progression (multiple myeloma, colorectal cancer)

    • Enhancing MEF2A activity in contexts where it suppresses tumor growth (certain gastric cancers)

    • Targeting the interaction between MEF2A and class II HDACs in leiomyosarcoma